BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9538020)

  • 1. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state.
    Ramachandra M; Ambudkar SV; Chen D; Hrycyna CA; Dey S; Gottesman MM; Pastan I
    Biochemistry; 1998 Apr; 37(14):5010-9. PubMed ID: 9538020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
    Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
    Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug binding and nucleotide hydrolyzability are essential requirements in the vanadate-induced inhibition of the human P-glycoprotein ATPase.
    Rao US
    Biochemistry; 1998 Oct; 37(42):14981-8. PubMed ID: 9778376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of P-glycoprotein ATPase by analogues of tetramethylrosamine: coupling of drug binding at the "R" site to the ATP hydrolysis transition state.
    Tombline G; Donnelly DJ; Holt JJ; You Y; Ye M; Gannon MK; Nygren CL; Detty MR
    Biochemistry; 2006 Jul; 45(26):8034-47. PubMed ID: 16800628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle.
    Qu Q; Russell PL; Sharom FJ
    Biochemistry; 2003 Feb; 42(4):1170-7. PubMed ID: 12549939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catalytic mechanism of P-glycoprotein.
    Senior AE
    Acta Physiol Scand Suppl; 1998 Aug; 643():213-8. PubMed ID: 9789563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
    Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
    Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
    Liu R; Sharom FJ
    Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
    Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
    Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionally similar vanadate-induced 8-azidoadenosine 5'-[alpha-(32)P]Diphosphate-trapped transition state intermediates of human P-glycoprotin are generated in the absence and presence of ATP hydrolysis.
    Sauna ZE; Smith MM; Muller M; Ambudkar SV
    J Biol Chem; 2001 Jun; 276(24):21199-208. PubMed ID: 11287418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP occlusion by P-glycoprotein as a surrogate measure for drug coupling.
    Tombline G; Holt JJ; Gannon MK; Donnelly DJ; Wetzel B; Sawada GA; Raub TJ; Detty MR
    Biochemistry; 2008 Mar; 47(10):3294-307. PubMed ID: 18275155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates.
    Kerr KM; Sauna ZE; Ambudkar SV
    J Biol Chem; 2001 Mar; 276(12):8657-64. PubMed ID: 11121420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport.
    Eckford PD; Sharom FJ
    Biochemistry; 2008 Dec; 47(51):13686-98. PubMed ID: 19049391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P glycoprotein and the mechanism of multidrug resistance.
    Váradi A; Szakács G; Bakos E; Sarkadi B
    Novartis Found Symp; 2002; 243():54-65; discussion 65-8, 180-5. PubMed ID: 11990782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein shows strong catalytic cooperativity between the two nucleotide sites.
    Senior AE; Bhagat S
    Biochemistry; 1998 Jan; 37(3):831-6. PubMed ID: 9454572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site.
    Urbatsch IL; Sankaran B; Weber J; Senior AE
    J Biol Chem; 1995 Aug; 270(33):19383-90. PubMed ID: 7642618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition state P-glycoprotein binds drugs and modulators with unchanged affinity, suggesting a concerted transport mechanism.
    Qu Q; Chu JW; Sharom FJ
    Biochemistry; 2003 Feb; 42(5):1345-53. PubMed ID: 12564938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein.
    Maki N; Moitra K; Ghosh P; Dey S
    J Biol Chem; 2006 Apr; 281(16):10769-77. PubMed ID: 16505485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1).
    Maki N; Dey S
    Biochem Pharmacol; 2006 Jul; 72(2):145-55. PubMed ID: 16729976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the vectorial nature of drug (substrate)-stimulated ATP hydrolysis by human P-glycoprotein.
    Sauna ZE; Smith MM; Müller M; Ambudkar SV
    J Biol Chem; 2001 Sep; 276(36):33301-4. PubMed ID: 11451943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.